On November 16, 2024, Dyadic International, Inc. announced the execution of a significant agreement with the Bill & Melinda Gates Foundation. The company has received a grant totaling $3,092,136.00 from the Gates Foundation. This grant is specifically designated to fund the cell line development of monoclonal antibodies geared towards combating respiratory syncytial virus and malaria. ...
Publicado el: 2024-11-28 07:00:55
Autor: MarketBeat News, Fuente: etfdailynews